Excellent preclinical data on Xeltis’ new restorative carotid artery have been presented today at the Third International Symposium on Vascular Tissue Engineering (ISVTE). The 12-month in vivo data showed excellent hemodynamic performance of Xeltis’ carotid artery, which was gradually replaced by neo-tissue with no signs of stenosis or dilatation one year after implantation.
“The data show the potential of Xeltis’ technology for small diameter vascular applications, which is an important clinical problem. There is a shortage of autologous vascular grafts and durability of commercially available permanent synthetic grafts is limited,” commented Xeltis CTO and Co-Founder, Martijn Cox. “This confirms the vast potential of our RestoreX technology for restorative vascular treatment,” he added.
ISVTE takes place 5-6 June at Nationwide Children’s Hospital in Columbus, Ohio (USA). The meeting attracts biologists, engineers and active clinicians in the field of vascular tissue engineering.
